Sun Pharma ups growth projection on Taro inclusion

02 Nov 2010 Evaluate

Though more clarity is to emerge on Israeli drug-maker Taro's operations, Sun Pharma has revised its guidance on topline growth to 35 per cent from the earlier projection of 20 per cent. Sun is still trying to get a handle on Taro's business and there were plans for “incremental investment” in Taro's facilities in Israel and Canada.

New investments in Taro's plants were approved after Sun took over and it would be on similar lines as it happens in Sun. Taro has shut down its Ireland plant and some equipment has been transferred to the Canada and Israel plants. The Ireland plant — that had also become a bone of contention between the two companies when they were locked in litigation — is not in “usable form”.

Taro brings to the table about 150 abbreviated new drug applications (ANDA – that allows sale in the US), and a pipeline of drugs that Sun does not have the capacity to make or does not have the time to bring to the market. Sun, on its part, will take Taro products to new geographies and will also look to strengthen Taro's pipeline by undertaking clinical studies on products.

crackcrack

Sun Pharma Inds. Share Price

1719.20 -18.30 (-1.05%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×